Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Moroctocog Alfa→

Moroctocog Alfa PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
284036-24-4
Molecular formula
Not available
Molecular weight
Not available
Drug class
Recombinant coagulation factor VIIIantihaemorrhagic biologic
Mechanism of action
Temporarily replaces deficient factor VIII in the intrinsic coagulation pathway. Factor VIII acts as a cofactor for activated factor IX, enabling factor X activation and downstream thrombin generation and fibrin clot formation.
Indications / reported uses
  • Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency), including perioperative management, under the authorised product indication.

Sources: https://www.ema.europa.eu/en/medicines/human/EPAR/refacto-af · https://www.pfizermedicalinformation.com/xyntha-lyophilized-powder/clinical-pharmacology

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Recombinant coagulation factor VIII; antihaemorrhagic biologic

Mechanism of action

Temporarily replaces deficient factor VIII in the intrinsic coagulation pathway. Factor VIII acts as a cofactor for activated factor IX, enabling factor X activation and downstream thrombin generation and fibrin clot formation.

General use cases

  • Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency), including perioperative management, under the authorised product indication.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Moroctocog Alfa PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Moroctocog Alfa Permitted Daily Exposure (PDE) report (the Moroctocog Alfa PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Moroctocog Alfa Occupational Exposure Limit (OEL) report (the Moroctocog Alfa OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.